Longevica Therapeutics Formed Scientific Advisory Board
The San Francisco biotech firm appointed a board to oversee its pivot toward clinical development.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you trust private biotech companies to successfully develop credible treatments to extend human lifespan?
Longevica Therapeutics has established a new scientific advisory board to guide its transition from foundational research to clinical execution. The company also announced that Dr. Prasun Mishra has taken on the role of Chief Executive Officer.
Why it matters
The formation of this advisory body signals a strategic shift for the organization as it moves its lifespan-extending research out of the laboratory and toward human clinical trials.
Longevica invested $13 million into a four-year program screening 1,033 small-molecule compounds. The firm utilizes predictive machine learning algorithms trained on outcomes from over 16,000 mammalian subjects.
The players
Longevica Therapeutics
This biotechnology company focuses on developing therapeutics that target aging mechanisms.
Dr. Prasun Mishra
He serves as the Chief Executive Officer tasked with leading the company's shift toward clinical development.
The Jackson Laboratory
This independent, nonprofit biomedical research institution hosted the company's four-year mammalian screening program.
The details
The biotech company developed two classes of therapeutics designed to address age-related diseases. By leveraging data from full-lifespan studies conducted at The Jackson Laboratory, the firm seeks to refine its mechanisms for human application.
Timeline
September 29, 2026: Longevica announced the formation of its new scientific advisory board.
The Tech Race
Longevica leverages data from the established infrastructure of The Jackson Laboratory to advance its proprietary lifespan-extension research. This effort represents a broader industry trend of applying predictive machine learning to biological datasets to accelerate drug discovery timelines.
The transition to clinical execution may eventually lead to new therapeutic options for age-related conditions. Investors and patients should monitor the company's pipeline progress as it moves closer to human trials.
The takeaway
Longevica's move reflects a maturation phase common for firms transitioning from big-data discovery to medical application. Future success will depend on whether its compound efficacy data holds up during human clinical testing.
Further reading
Learn more about the latest industry developments in Biotech.
More information
View the current Longevica company pipeline and research on the company's official site.
Live Poll
Do you trust private biotech companies to successfully develop credible treatments to extend human lifespan?
